PHILIP-MORRIS-INTERNATIO
23.4.2019 19:31:04 CEST | Business Wire | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today reaffirmed its vision for the future: To achieve a smoke-free world; that is, one without cigarettes. For the hundreds of millions of men and women globally who will otherwise continue to smoke, PMI’s goal is to switch them to nicotine-containing products that are scientifically substantiated as better choices than continuing to smoke. Our strong belief—if you don’t smoke, don’t start—begins with a continued and robust focus on preventing youth from beginning to smoke or use nicotine products.
“Given the rapid pace of innovation in the tobacco products space, we are emphatic that youth should not use any tobacco- or nicotine-containing product. Nicotine is addictive. It is not risk-free, and it poses particular risks for adolescents. We know that great care must be taken to achieve our smoke-free goal. Youth should not become nicotine users. Former smokers and never smokers should not return to, or pick up, the tobacco or nicotine habit. The entire effort must be on providing better choices to the men and women who smoke today,” reiterated André Calantzopoulos, CEO of Philip Morris International.
He continues: “PMI takes that responsibility seriously. Our ‘Good Conversion Practices ’ serve as the company’s bedrock for encouraging adult smokers to switch while working to prevent unintended use in the countries where we sell innovative products that do not burn tobacco. In our IQOS stores, we refuse to offer these products to people who have never smoked or those who have quit smoking. We are also clear that these products are not risk-free or a safe alternative to cigarettes. Similarly, our marketing standards are rooted in the principle that we market and sell our products to adult smokers.”
“Increasing the legal age of purchase for tobacco and nicotine products can play an important role in further guarding against youth use of such products, together with access control and education that has to expand from cigarette smoking prevention to the use of any nicotine product. However, that effort must first begin with companies themselves. Tobacco and e-cigarette manufacturers must have the right approach, the right product and the right science as well as robust post-market surveillance programs to ensure new tobacco and nicotine technologies reach their intended audience—men and women who currently smoke. PMI turned to commercializing our smoke-free products only after we were confident we got all three right,” said PMI COO Jacek Olczak.
In countries where IQOS, PMI’s heated tobacco system, is sold, real-world data shows we are reaching current adult smokers—in other words, the correct audience. In Japan (the largest market for IQOS), 98 percent of IQOS adopters were tobacco users before switching, and globally the average IQOS user is aged 30 to 49. PMI is reaching current adult smokers—again: the correct audience.
In the U.S., PMI affirms, the best way tobacco and e-cigarette companies can address the most serious issues, such as underage use, is by availing themselves of the opportunity presented by review and authorization by the Food and Drug Administration (FDA). More than two years ago, PMI put IQOS, our electrically heated tobacco system, for review before the agency. No other company has presented to the FDA a scientific evidence package as comprehensive as PMI has for its heated tobacco system. We are hopeful FDA will soon authorize IQOS for sale in the U.S.
“There is a balance that must be struck. Youth should not use nicotine products. That is beyond dispute. At the same time, public policy needs to recognize the role that new smoke-free tobacco and other nicotine-containing products can play in helping move adult smokers away from cigarettes. Achieving this balance is absolutely necessary to realizing a true public health breakthrough, and requires close coordination with the regulatory agencies pre and most importantly post-market,” adds Mr. Calantzopoulos.
To date, PMI has invested over USD$6 billion in the research, development, manufacturing and commercialization of smoke-free products and dedicated 400+ scientists and engineers to research and development. Recently, PMI launched its “Unsmoke Your World ” initiative designed to deliver a clear and simple message to adults who currently smoke and those who do not: If you don’t smoke, don’t start; If you smoke, quit; If you don’t quit, change.
-ENDS-
Philip Morris International: Building a Smoke-Free Future
Philip
Morris International (PMI) is leading a transformation in the tobacco
industry to create a smoke-free future and ultimately replace cigarettes
with smoke-free products to the benefit of adults who would otherwise
continue to smoke, society, the company and its shareholders. PMI is a
leading international tobacco company engaged in the manufacture and
sale of cigarettes, smoke-free products and associated electronic
devices and accessories, and other nicotine-containing products in
markets outside the U.S. PMI is building a future on a new category of
smoke-free products that, while not risk-free, are a much better choice
than continuing to smoke. Through multidisciplinary capabilities in
product development, state-of-the-art facilities and scientific
substantiation, PMI aims to ensure that its smoke-free products meet
adult consumer preferences and rigorous regulatory requirements. For
more information, see our PMI
and PMIScience
websites.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190423005816/en/
Contact:
Media enquiries Ryan Sparrow, Philip Morris International T: +41 79 549 1968 E: ryan.sparrow@pmi.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
